152
Participants
Start Date
February 28, 2010
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2013
Ranibizumab
Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
ranibizumab
Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
Eye Care Specialists, Kingston
Johns Hopkins University Wilmer Eye Institute, Baltimore
Retina Group of Florida, Fort Lauderdale
Black Hills Eye Institute, Rapid City
Illinois Retina Associates, Joliet
University of Kansas, Prairie Village
Texas Retina Associates, Arlington
Doheny Eye Institute, Los Angeles
Retina Vitreous Associates, Beverly Hills
Retina Macula Institute, Torrance
University of California San Diego, La Jolla
East Bay Retina Institute, Oakland
Retina Institute of Hawaii, Honolulu
Collaborators (1)
Juvenile Diabetes Research Foundation
OTHER
Johns Hopkins University
OTHER